Logo image of ABVX

ABIVAX SA-ADR (ABVX) Stock Fundamental Analysis

NASDAQ:ABVX - Nasdaq - US00370M1036 - ADR - Currency: USD

10.3  +0.35 (+3.52%)

Fundamental Rating

1

Overall ABVX gets a fundamental rating of 1 out of 10. We evaluated ABVX against 556 industry peers in the Biotechnology industry. Both the profitability and financial health of ABVX have multiple concerns. While showing a medium growth rate, ABVX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ABVX has reported negative net income.
In the past year ABVX has reported a negative cash flow from operations.
In the past 5 years ABVX always reported negative net income.
In the past 5 years ABVX always reported negative operating cash flow.
ABVX Yearly Net Income VS EBIT VS OCF VS FCFABVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -85.88%, ABVX is not doing good in the industry: 71.94% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -434.26%, ABVX is doing worse than 76.44% of the companies in the same industry.
Industry RankSector Rank
ROA -85.88%
ROE -434.26%
ROIC N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX Yearly ROA, ROE, ROICABVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX Yearly Profit, Operating, Gross MarginsABVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, ABVX has more shares outstanding
Compared to 5 years ago, ABVX has more shares outstanding
Compared to 1 year ago, ABVX has a worse debt to assets ratio.
ABVX Yearly Shares OutstandingABVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX Yearly Total Debt VS Total AssetsABVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ABVX has an Altman-Z score of -3.35. This is a bad value and indicates that ABVX is not financially healthy and even has some risk of bankruptcy.
ABVX has a Altman-Z score of -3.35. This is comparable to the rest of the industry: ABVX outperforms 47.66% of its industry peers.
ABVX has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
ABVX has a Debt to Equity ratio of 1.29. This is in the lower half of the industry: ABVX underperforms 79.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z -3.35
ROIC/WACCN/A
WACCN/A
ABVX Yearly LT Debt VS Equity VS FCFABVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.82 indicates that ABVX should not have too much problems paying its short term obligations.
ABVX has a worse Current ratio (1.82) than 78.24% of its industry peers.
ABVX has a Quick Ratio of 1.82. This is a normal value and indicates that ABVX is financially healthy and should not expect problems in meeting its short term obligations.
ABVX has a Quick ratio of 1.82. This is in the lower half of the industry: ABVX underperforms 76.98% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
ABVX Yearly Current Assets VS Current LiabilitesABVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.74% over the past year.
EPS 1Y (TTM)16.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.91% yearly.
ABVX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 136.65% yearly.
EPS Next Y-4.62%
EPS Next 2Y24.86%
EPS Next 3Y27.61%
EPS Next 5Y32.91%
Revenue Next Year588.98%
Revenue Next 2Y-12.67%
Revenue Next 3Y163.09%
Revenue Next 5Y136.65%

3.3 Evolution

ABVX Yearly Revenue VS EstimatesABVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ABVX Yearly EPS VS EstimatesABVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABVX. In the last year negative earnings were reported.
Also next year ABVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX Price Earnings VS Forward Price EarningsABVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX Per share dataABVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

ABVX's earnings are expected to grow with 27.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.86%
EPS Next 3Y27.61%

More info and screens

0

5. Dividend

5.1 Amount

ABVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIVAX SA-ADR

NASDAQ:ABVX (7/21/2025, 2:50:57 PM)

10.3

+0.35 (+3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-02 2025-06-02
Earnings (Next)08-11 2025-08-11
Inst Owners42.26%
Inst Owner Change-0.06%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap653.58M
Analysts87.69
Price Target31.51 (205.92%)
Short Float %2.55%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.66%
PT rev (3m)1.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.03%
EPS NY rev (3m)0.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.82
P/tB 36.06
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0
BVpS0.75
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.88%
ROE -434.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z -3.35
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.47%
EPS Next Y-4.62%
EPS Next 2Y24.86%
EPS Next 3Y27.61%
EPS Next 5Y32.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year588.98%
Revenue Next 2Y-12.67%
Revenue Next 3Y163.09%
Revenue Next 5Y136.65%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.9%
EBIT Next 3Y29.55%
EBIT Next 5Y40.7%
FCF growth 1Y-58.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.62%
OCF growth 3YN/A
OCF growth 5YN/A